Hint mode is switched on Switch off
For swift navigation between sections

Allergan Sales
LEI 254900TUPGX2F5Y3AU71

Organization name
Allergan Sales, LLC
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
  • M/S&P/F
    *** / *** / ***
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds
  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Quotes

Request sent
Access denied
Quotes provided by information providers are indicative in nature

Profile

Allergan Sales, LLC (f.n.a.Forest Laboratories, Inc. (Forest)) develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. The Company’s products include Namenda, the Company's NMDA antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic is a beta-blocker for the treatment of hypertension; Linzess is a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza is a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd is an SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with major depressive disorder (MDD).

Awards

Documentation

Stocks

Latest issues

Public debt by currencies

Codes

  • LEI
    254900TUPGX2F5Y3AU71
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • ICB
    4,500 Health Care
  • NACE
    *** ***
  • NAICS
    *** ***
Registration is required to get access.